Clinical applicability of diagnostic biomarkers in early‐onset cognitive impairment

• DOI: 10.1111/ene.13945
• Publication Date: 2019-02-22T04:04:54Z
• Authors: N. Falgàs; A. Tort‐Merino; M. Balasa; S. Borrego‐Écija; M. Castellví; J. Olives; B. Bosch; G. Férnandez‐Vill...; A. Antonell; J. M. Augé; F. Lomeña; A. Perissinotti; N. Bargalló; R. Sánchez‐Valle; A. Lladó
• Keywords: Tolerability

Several diagnostic biomarkers are currently available for clinical use in early-onset cognitive impairment. The decision on which biomarker is used each patient depends several factors such as its predictive value or tolerability.There were a total of 40 subjects with complaints (<65 years age): 26 Alzheimer's disease (AD), five frontotemporal dementia and nine suspicion non-neurodegenerative disorder. Clinical neuropsychological evaluation, lumbar puncture cerebrospinal fluid (CSF) AD core biochemical marker determination, medial temporal atrophy evaluation magnetic resonance imaging, amyloid-positron emission tomography (PET) 18 F-fluorodeoxyglucose-PET performed. Neurologists provided pre- post-biomarker diagnosis, together confidence clinical/therapeutic management. Patients scored the tolerability procedure.Cerebrospinal amyloid-PET increased (77.4%-86.2% after CSF, 92.4% amyloid-PET, P < 0.01) conditions (53.6%-75% 95% 0.05). Biomarker results led to (32.5%) treatment changes. All tests well tolerated.Biomarker procedures tolerated have an important diagnostic/therapeutic impact